Immunomodulatory agents with antivascular activity in the treatment of non-small cell lung cancer: Focus on TLR9 agonists, IMiDs and NGR-TNF

Journal of Oncology

Volumn , Issue , 2010, Pages

  Corti, Angelo ^a   Giovannini, Monica ^a   Belli, Carmen ^a   Villa, Eugenio ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AGATOLIMOD; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; ENMD 0995; GEMCITABINE; LENALIDOMIDE; MELPHALAN; MONOCLONAL ANTIBODY; OLIGONUCLEOTIDE; PACLITAXEL; PLATINUM; POMALIDOMIDE; TAXANE DERIVATIVE; THALIDOMIDE; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR DERIVATIVE; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; CANCER REGRESSION; CHILL; COLORECTAL CANCER; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FATIGUE; HEAT; HUMAN; IMMUNE RESPONSE; INJECTION SITE REACTION; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MELANOMA; MULTIPLE MYELOMA; MYALGIA; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PAIN; PLEURA MESOTHELIOMA; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SOLID TUMOR; SWELLING; THROMBOCYTOPENIA; TREATMENT PLANNING; VASCULAR TUMOR;

EID: 77954649329     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2010/732680     Document Type: Review

References (80)

1. American Cancer Society, Cancer Facts and Figures 2005 Atlanta, Ga, USA American Cancer Society
2. Ferrigno D., Buccheri G., Second-line chemotherapy for recurrent non-small cell lung cancer: do new agents make a difference? Lung Cancer 2000 29 2 91 104
3. Hoffman P. C., Mauer A. M., Vokes E. E., Lung cancer The Lancet 2000 355 9202 479 485
4. O'Mahony D., Kummar S., Gutierrez M. E., Non-small-cell lung cancer vaccine therapy: a concise review Journal of Clinical Oncology 2005 23 35 9022 9028
5. Tishler M., Shoenfeld Y., BCG immunotherapyfrom pathophysiology to clinical practice Expert Opinion on Drug Safety 2006 5 2 225 229
6. Apetoh L., Ghiringhelli F., Tesniere A., The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy Immunological Reviews 2007 220 1 47 59
7. Chen K., Huang J., Gong W., Iribarren P., Dunlop N. M., Wang J. M., Toll-like receptors in inflammation, infection and cancer International Immunopharmacology 2007 7 10 1271 1285
8. Hemmi H., Takeuchi O., Kawai T., A Toll-like receptor recognizes bacterial DNA Nature 2000 408 6813 740 745
9. Rakoff-Nahoum S., Paglino J., Eslami-Varzaneh F., Edberg S., Medzhitov R., Recognition of commensal microflora by Toll-like receptors is required for intestinal homeostasis Cell 2004 118 2 229 241
10. Vollmer J., Krieg A. M., Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists Advanced Drug Delivery Reviews 2009 61 3 195 204
11. Cafaro A., Titti F., Fracasso C., Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P) Vaccine 2001 19 2022 2862 2877
12. Carpentier A. F., Xie J., Mokhtari K., Delattre J.-Y., Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs Clinical Cancer Research 2000 6 6 2469 2473
13. Dalpke A., Zimmermann S., Heeg K., CpG DNA in the prevention and treatment of infections Bio Drugs 2002 16 6 419 431
14. Sabroe I., Parker L. C., Wilson A. G., Whyte M. K. B., Dower S. K., Toll-like receptors: their role in allergy and non-allergic inflammatory disease Clinical and Experimental Allergy 2002 32 7 984 989
15. Van Uden J., Raz E., Immunostimulatory DNA and applications to allergic disease Journal of Allergy and Clinical Immunology 1999 104 5 902 910
16. Wang H., Rayburn E., Zhang R., Synthetic oligodeoxynucleotides containing deoxycytidyl-deoxyguanosine dinucleotides (CpG ODNs) and modified analogs as novel anticancer therapeutics Current Pharmaceutical Design 2005 11 22 2889 2907
17. Klinman D. M., Yi A.-K., Beaucage S. L., Conover J., Krieg A. M., CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon Proceedings of the National Academy of Sciences of the United States of America 1996 93 7 2879 2883
18. Klinman D. M., Immunotherapeutic uses of CpG oligodeoxynucleotides Nature Reviews Immunology 2004 4 4 249 258
19. Krieg A. M., CpG motifs in bacterial DNA and their immune effects Annual Review of Immunology 2002 20 709 760
20. Takeshita F., Gursel I., Ishii K. J., Suzuki K., Gursel M., Klinman D. M., Signal transduction pathways mediated by the interaction of CpG DNA with Toll-like receptor 9 Seminars in Immunology 2004 16 1 17 22
21. Wang H., Rayburn E., Zhang R., Synthetic oligodeoxynucleotides containing deoxycytidyl-deoxyguanosine dinucleotides (CpG ODNs) and modified analogs as novel anticancer therapeutics Current Pharmaceutical Design 2005 11 22 2889 2907
22. Kandimalla E. R., Bhagat L., Li Y., Immunomodulatory oligonucleotides containing a cytosine-phosphate- 2 ′ -deoxy-7-deazaguanosine motif as potent Toll-like receptor 9 agonists Proceedings of the National Academy of Sciences of the United States of America 2005 102 19 6925 6930
23. Kandimalla E. R., Bhagat L., Zhu F.-G., A dinucleotide motif in oligonucleotides shows potent immunomodulatory activity and overrides species-specific recognition observed with CpG motif Proceedings of the National Academy of Sciences of the United States of America 2003 100 2 14303 14308
24. Li Y., Kandimalla E. R., Yu D., Agrawal S., Oligodeoxynucleotides containing synthetic immunostimulatory motifs augment potent Th1 immune responses to HBsAg in mice International Immunopharmacology 2005 5 6 981 991
25. Bhagat L., Zhu F.-G., Yu D., CpG penta- and hexadeoxyribonucleotides as potent immunomodulatory agents Biochemical and Biophysical Research Communications 2003 300 4 853 861
26. Kandimalla E. R., Bhagat L., Wang D., Divergent synthetic nucleotide motif recognition pattern: design and development of potent immunomodulatory oligodeoxyribonucleotide agents with distinct cytokine induction profiles Nucleic Acids Research 2003 31 9 2393 2400
27. Yu D., Zhu F.-G., Bhagat L., Potent CpG oligonucleotides containing phosphodiester linkages: in vitro and in vivo immunostimulatory properties Biochemical and Biophysical Research Communications 2002 297 1 83 90
28. Murad Y. M., Clay T. M., Lyerly H. K., Morse M. A., CPG-7909 (PF-3512676, ProMune): Toll-like receptor-9 agonist in cancer therapy Expert Opinion on Biological Therapy 2007 7 8 1257 1266
29. Chen K., Huang J., Gong W., Iribarren P., Dunlop N. M., Wang J. M., Toll-like receptors in inflammation, infection and cancer International Immunopharmacology 2007 7 10 1271 1285
30. Drugs R D International Immunopharmacology 2006 7 5 312 316
31. Angiolillo A. L., Sgadari C., Tosato G., A role for the interferon-inducible protein 10 in inhibition of angiogenesis by interleukin-12 Annals of the New York Academy of Sciences 1996 795 158 167
32. Geary R. S., Leeds J. M., Henry S. P., Monteith D. K., Levin A. A., Antisense oligonucleotide inhibitors for the treatment of cancer. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides Anti-Cancer Drug Design 1997 12 5 383 393
33. Hofmann M. A., Kors C., Audring H., Walden P., Sterry W., Trefzer U., Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma Journal of Immunotherapy 2008 31 5 520 527
34. Thompson J. A., Kuzel T., Drucker B. J., Urba W., Bukowski R., Safety and efficacy of PF-3512676 for the treatment of stage IV renal cell carcinoma: an open-label, multicenter phase I/II study Clinical Genitourinary Cancer 2009 7 3 E58 E65
35. Leonard J. P., Link B. K., Emmanouilides C., Phase I trial of Toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non-Hodgkin's lymphoma Clinical Cancer Research 2007 13 20 6168 6174
36. Link B. K., Ballas Z. K., Weisdorf D., Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma Journal of Immunotherapy 2006 29 5 558 568
37. Bradbury P. A., Shepherd F. A., Immunotherapy for lung cancer Journal of Thoracic Oncology 2008 3 6 S164 S170
38. Yamada K., Nakao M., Fukuyama C., Phase I study of TLR9 agonist PF-3512676 in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer Cancer Science 2010 101 1 188 195
39. Leichman G., Gravenor D., Woytowitz D., CPG 7909, a TLR9 agonist, added to first line taxane/platinum for advanced non-small cell lung cancer, a randomized, controlled phase II study Journal of Clinical Oncology 2005 23 16S. abstract 7036
40. Manegold C., Gravenor D., Woytowitz D., Randomized phase II trial of a Toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer Journal of Clinical Oncology 2008 26 24 3979 3986
41. O'Mahony D., Kummar S., Gutierrez M. E., Non-small-cell lung cancer vaccine therapy: a concise review Journal of Clinical Oncology 2005 23 35 9022 9028
42. Hirsh V., Boyer M., Rosell R., Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 as first line treatment of advanced non-small cell lung cancer (NSCLC) Journal of Clinical Oncology 2008 26 supplement. abstract no. 8016
43. Manegold C., Thatcher N., Benner R. J., Randomized phase III trial of gemcitabine/cisplatin with or without PF-3512676 as first line treatment of advanced non-small cell lung cancer (NSCLC) Journal of Clinical Oncology 2008 26. abstract no. 8017
44. Mellin G. W., Katzenstein M., The saga of thalidomide. Neuropathy to embryopathy, with case reports of congenital anomalies The New England Journal of Medicine 1962 267 1184 1192
45. Kelsey F. O., Thalidomide update: regulatory aspects Teratology 1988 38 3 221 226
46. D'Amato R. J., Loughnan M. S., Flynn E., Folkman J., Thalidomide is an inhibitor of angiogenesis Proceedings of the National Academy of Sciences of the United States of America 1994 91 9 4082 4085
47. Kenyon B. M., Browne F., D'Amato R. J., Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization Experimental Eye Research 1997 64 6 971 978
48. Press Release, Thalomid sNDA Granted FDA Approval For Treatment of Newly Diagnosed Multiple Myeloma. 2007
49. Anderson K. C., Lenalidomide and thalidomide: mechanisms of actionsimilarities and differences Seminars in Hematology 2005 42 supplement 4 S3 S8
50. Chanan-Khan A. A., Cheson B. D., Lenalidomide for the treatment of B-cell malignancies Journal of Clinical Oncology 2008 26 9 1544 1552
51. Muller G. W., Chen R., Huang S.-Y., Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production Bioorganic and Medicinal Chemistry Letters 1999 9 11 1625 1630
52. Niwayama S., Turk B. E., Liu J. O., Potent inhibition of tumor necrosis factor-alpha production by tetrafluorothalidomide and tetrafluorophthalimides Journal of Medicinal Chemistry 1996 39 16 3044 3045
53. Corral L. G., Haslett P. A. J., Muller G. W., Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha Journal of Immunology 1999 163 1 380 386
54. Bartlett J. B., Dredge K., Dalgleish A. G., The evolution of thalidomide and its IMiD derivatives as anticancer agents Nature Reviews Cancer 2004 4 4 314 322
55. Corral L. G., Kaplan G., Immunomodulation by thalidomide and thalidomide analogues Annals of the Rheumatic Diseases 1999 58 supplement 1 I107 I113
56. Galustian C., Meyer B., Labarthe M.-C., The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells Cancer Immunology Immunotherapy 2009 58 7 1033 1045
57. Dredge K., Marriott J. B., Macdonald C. D., Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects British Journal of Cancer 2002 87 10 1166 1172
58. Chauhan D., Singh A. V., Ciccarelli B., Richardson P. G., Palladino M. A., Anderson K. C., Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma Blood 2010 115 4 834 845
59. Lu L., Payvandi F., Wu L., The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions Microvascular Research 2009 77 2 78 86
60. Mangiameli D. P., Blansfield J. A., Kachala S., Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma Journal of Translational Medicine 2007 5, article 38
61. Gupta D., Treon S. P., Shima Y., Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications Leukemia 2001 15 12 1950 1961
62. Lentzsch S., Rogers M. S., LeBlanc R., S-3-amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice Cancer Research 2002 62 8 2300 2305
63. Eisen T., Trefzer U., Hamilton A., Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma Cancer 2010 116 1 146 154
64. Miller A. A., Case D., Harmon M., Phase I study of lenalidomide in solid tumors Journal of Thoracic Oncology 2007 2 5 445 449
65. Dahut W. L., Aragon-Ching J. B., Woo S., Phase I study of oral lenalidomide in patients with refractory metastatic cancer Journal of Clinical Pharmacology 2009 49 6 650 660
66. Sanborn S. L., Gibbons J., Krishnamurthi S., Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors Investigational New Drugs 2009 27 5 453 460
67. Kalmadi S., Davis M., Dowlati A., Phase I trial of three-weekly docetaxel, carboplatin and oral lenalidomide (Revlimid) in patients with advanced solid tumors Investigational New Drugs 2007 25 3 211 216
68. Curnis F., Sacchi A., Borgna L., Magni F., Gasparri A., Corti A., Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13) Nature Biotechnology 2000 18 11 1185 1190
69. Curnis F., Arrigoni G., Sacchi A., Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells Cancer Research 2002 62 3 867 874
70. Di Matteo P., Curnis F., Longhi R., Immunogenic and structural properties of the Asn-Gly-Arg (NGR) tumor neovasculature-homing motif Molecular Immunology 2006 43 10 1509 1518
71. Curnis F., Sacchi A., Corti A., Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration Journal of Clinical Investigation 2002 110 4 475 482
72. Corti A., Ponzoni M., Tumor vascular targeting with tumor necrosis factor alpha and chemotherapeutic drugs Annals of the New York Academy of Sciences 2004 1028 104 112
73. Sacchi A., Gasparri A., Gallo-Stampino C., Toma S., Curnis F., Corti A., Synergistic antitumor activity of cisplatin, paclitaxel, and gemcitabine with tumor vasculature-targeted tumor necrosis factor-alpha Clinical Cancer Research 2006 12 1 175 182
74. Balza E. L., Mortara L., Sassi F., Targeted delivery of tumor necrosis factor-alpha to tumor vessels induces a therapeutic T cell-mediated immune response that protects the host against syngeneic tumors of different histologic origin Clinical Cancer Research 2006 12 8 2575 2582
75. Palladino M. A., Shalaby M. R., Kramer S. M., Characterization of the antitumor activities of human tumor necrosis factor-alpha and the comparison with other cytokines: induction of tumor-specific immunity Journal of Immunology 1987 138 11 4023 4032
76. Bellone M., Mondino A., Corti A., Vascular targeting, chemotherapy and active immunotherapy: teaming up to attack cancer Trends in Immunology 2008 29 5 235 241
77. Bennicelli E., Santoro A., Rimassa L., Phase II study of NGR-HTNF, a novel vascular targeting agent in colorectal cancer patients refractory to standard regimens Annals of Oncology 2008 19 supplement 9. abstract no. H16, ix77
78. Citterio G., Santoro A., Pressiani T., Safety and antitumor activity of NGR-HTNF, a selective vascular targeting agent, administered at low dose in pretreated patients with hepatocellular carcinoma: preliminary results of a phase II trial Annals of Oncology 2008 19 supplement 8. abstract no. 546P, viii178
79. Gregorc V., Zucali P., Ceresoli G., Phase II trial of NGR-HTNF, a novel vascular targeting agent, in malignant pleural mesothelioma Annals of Oncology 2008 19 supplement 9. abstract no. F8, ix57
80. van Laarhoven H., Fiedler W., Desar I. M., Phase I and DCE-MRI evaluation of NGR-TNF, a novel vascular targeting agent, in patients with solid tumors (EORTC 16041) Journal of Clinical Oncology 2008 26 supplement. abstract no. 3521